InfuSystem Holdings (INFU) AI Stock Analysis

• Market Cap: $128.37M
• Dividend Yield: N/A
• Average Volume (3M): 248.37K
• Price to Earnings (P/E): 41.7
• Beta (1Y): 1.27
• Revenue Growth: 7.98%
• EPS Growth: 3304.55%
• Country: US
• Employees: 502
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.01
• Shares Outstanding: 20,975,264
• 10 Day Avg. Volume: 447,751
• 30 Day Avg. Volume: 248,365
• PEG Ratio: 0.82
• Price to Book (P/B): 2.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 7.68
• Enterprise Value/Market Cap: 1.22
• Enterprise Value/Revenue: 0.29
• Enterprise Value/Gross Profit: 2.16
• Enterprise Value/Ebitda: 2.20
• 1Y Price Target: $12.25
• Price Target Upside: 100.16% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 76 Outperform
• Price Target: $7.00 ▲(14.38%Upside)

InfuSystem Holdings exhibits strong financial performance with robust revenue growth and efficient cash flow management. Technical analysis supports a positive trend, while recent earnings call and corporate events highlight positive sentiment and strategic positioning. However, the high P/E ratio indicates potential overvaluation. Overall, the stock is solid but has room for improvement in profitability and valuation metrics.

Positive Factors

Financial Performance

The Company showed notable progress in gross margin improvement of 122 basis points Y/Y and AEBITDA margin improvement of 282 basis points Y/Y.

Operating Cash Flow

Operating cash flow was $20.5M in 2024, an 82% increase Y/Y.

Negative Factors

Earnings

EPS of $0.04 was below our estimate and consensus of $0.08 and $0.09, respectively.

Revenue

Revenue came in below our forecast and consensus due to delays in onboarding new wound care initiatives as the Company looks to improve referral processes with newer partners.

InfuSystem Holdings Business Overview & Revenue Model

Company Description

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

How the Company Makes Money

InfuSystem Holdings generates revenue through the rental, sale, and servicing of infusion pumps and related medical equipment. The company's primary revenue streams include equipment rental agreements with healthcare providers, where InfuSystem supplies and maintains the equipment needed for patient care. Additionally, InfuSystem earns income from the sale of infusion pumps and medical supplies, as well as providing repair and maintenance services. The company benefits from partnerships with healthcare facilities and networks, which contribute to a steady demand for its equipment and services. InfuSystem's revenue model is also supported by long-term contracts and agreements that ensure continuous cash flow from recurring service fees and equipment rentals.

InfuSystem Holdings Financial Statement Overview

Summary

InfuSystem Holdings exhibits strong revenue growth and efficient cash flow management, with a stable balance sheet. However, there's room for improvement in profitability and return on equity.

Income Statement

InfuSystem Holdings has shown a consistent revenue growth trajectory with a TTM revenue of $137.6M, reflecting a growth rate of approximately 2.02%. The gross profit margin stands solid at 52.75%, indicating efficient cost management. However, the net profit margin of 3.08% suggests room for improvement in profitability. EBITDA margin is robust at 13.05%, supporting strong operational performance.

Balance Sheet

The company's balance sheet reveals a debt-to-equity ratio of 0.60, which is manageable but indicates a reliance on debt financing. The equity ratio is 52.89%, showcasing a stable asset base. Return on equity is moderate at 7.67%, suggesting reasonable returns to shareholders but with potential improvement needed.

Cash Flow

InfuSystem demonstrates strong cash flow management with a free cash flow growth rate of 518.13% in the TTM period. The operating cash flow to net income ratio of 5.17 indicates strong cash conversion, while the free cash flow to net income ratio of 3.84 reflects efficient capital allocation and liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	137.58M	134.86M	125.78M	109.91M	102.38M	97.39M
Gross Profit	72.55M	70.40M	63.11M	62.57M	60.20M	58.76M
EBITDA	17.96M	20.03M	16.50M	15.09M	17.15M	22.82M
Net Income	4.23M	2.35M	872.00K	18.00K	1.42M	17.33M
Balance Sheet
Total Assets	99.39M	103.61M	102.92M	99.39M	97.59M	96.99M
Cash, Cash Equivalents and Short-Term Investments	165.00K	527.00K	231.00K	165.00K	186.00K	9.65M
Total Debt	36.92M	28.42M	36.37M	36.92M	36.77M	42.66M
Total Liabilities	51.38M	46.09M	50.61M	51.38M	49.31M	56.24M
Stockholders Equity	48.00M	57.53M	52.30M	48.00M	48.27M	40.75M
Cash Flow
Free Cash Flow	16.24M	2.63M	106.00K	2.44M	1.66M	3.37M
Operating Cash Flow	21.86M	20.46M	11.22M	17.52M	18.32M	20.28M
Investing Cash Flow	-15.48M	-13.24M	-6.73M	-11.48M	-21.32M	-12.16M
Financing Cash Flow	-5.70M	-6.92M	-4.42M	-6.06M	-6.46M	-1.12M

InfuSystem Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INFU, the sentiment is Neutral. The current price of 6.12 is below the 20-day moving average (MA) of 6.12, above the 50-day MA of 5.62, and below the 200-day MA of 6.88, indicating a neutral trend. The MACD of 0.17 indicates Positive momentum. The RSI at 52.74 is Neutral, neither overbought nor oversold. The STOCH value of 76.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for INFU.

InfuSystem Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	79 Outperform	$187.75M	15.30	10.59%	2.11%	-19.92%	-16.22%
INFU	76 Outperform	$128.37M	41.69	5.94%	―	7.98%	3304.55%
STXS	63 Neutral	$196.94M	―	-179.82%	―	1.50%	-20.00%
KRMD	61 Neutral	$167.49M	―	-29.87%	―	19.65%	60.28%
Sector *	48 Neutral	AU$2.43B	4.28	-64.25%	2.88%	35.15%	13.63%
SMTI	44 Neutral	$252.50M	―	-28.58%	―	34.65%	-128.56%
MLSS	42 Neutral	$57.05M	―	-88.36%	―	-9.13%	30.04%

InfuSystem Holdings Corporate Events

InfuSystem Holdings Announces New CEO Employment Agreement

InfuSystem Holdings, Inc. announced a Second Amended and Restated Employment Agreement with its President and CEO, Carrie Lachance, reflecting her transition from COO to CEO on May 19, 2025. The agreement includes changes in compensation, stock options, and performance-based incentives, along with severance benefits and confidentiality provisions. Additionally, on May 15, 2025, the company’s stockholders approved Charter Amendments to its Certificate of Incorporation, removing outdated provisions and designating exclusive forums for certain claims.

The most recent analyst rating on (INFU) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.

InfuSystem Holdings Approves Equity Plan Amendment, New Chairman

At the 2025 Annual Meeting of Stockholders held on May 15, 2025, InfuSystem Holdings, Inc. announced the approval of the Second Amendment to its 2021 Equity Incentive Plan, increasing the maximum number of shares reserved for issuance to 6,000,000. This amendment, along with other approved proposals, aims to enhance the company’s operational flexibility and governance structure. Additionally, Ronald Hundzinski was elected as the Chairman of the Board of Directors, reflecting a shift in leadership dynamics. The meeting also saw the approval of several amendments to the company’s Certificate of Incorporation, including changes to forum selection for stockholder actions and officer exculpation, as well as the ratification of Deloitte & Touche LLP as the independent accounting firm for 2025.

The most recent analyst rating on (INFU) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.

InfuSystem Holdings Reports Record 2024 Revenue Growth

InfuSystem Holdings announced its financial performance for 2024, reporting a record revenue of $134.9 million, marking six consecutive years of revenue growth with a compound annual growth rate (CAGR) of 12%. The company also highlighted its strong balance sheet and substantial annual cash flow, positioning it well for future growth. InfuSystem’s strategic initiatives include expanding its device solutions and patient services, with a focus on oncology, pain management, and wound care. The company has established significant partnerships and distribution agreements, enhancing its market presence and service capabilities.

InfuSystem Holdings to Announce Q1 2025 Results

InfuSystem Holdings, Inc. announced that it will release its first quarter 2025 financial results on May 8, 2025, before the market opens. The company will also host a conference call on the same day to discuss the results, providing stakeholders an opportunity to gain insights into the company’s financial performance and strategic direction.

InfuSystem Holdings Announces CEO Transition in 2025

On April 1, 2025, InfuSystem Holdings, Inc. announced the upcoming departure of CEO Richard A. DiIorio, effective May 19, 2025, with Carrie Lachance set to succeed him. Lachance, who has been with the company since 2010 and served in various leadership roles, is expected to lead the company into its next growth phase. The transition is part of a planned succession, with DiIorio remaining as an advisor during the transition. The company reaffirmed its 2025 financial guidance, projecting revenue growth of 8-10% and an adjusted EBITDA margin exceeding 18.8%, indicating continued confidence in its operational performance despite ongoing investments.